Astrazeneca: ‘We’re too big to base our CEO’s pay on FTSE 100 peers’ February 18, 2025 Astrazeneca is too big and complex to base its chief executive’s pay packet on the rest of the FTSE index, according to the chair of its remuneration committee. Writing in the pharmaceutical giant’s annual report, chair Sheri McCoy said “UK-listed FTSE companies are not the right peer group for us to use” given the group’s [...]
Astrazeneca revenue surges amid Chinese import tax allegations February 6, 2025 Astrazeneca’s revenue jumped 21 per cent last year despite growing troubles over its presence in China. The pharmaceutical giant recorded $54bn (£43.3bn) in revenue for the year, a jump of 21 per cent on 2023’s levels. In its full-year results, the largest FTSE 100 firm revealed that revenue in Europe had skyrocketed 37 per cent. [...]
Astrazeneca: FTSE 100 giant shrugs off China worries with profit upgrade November 12, 2024 Pharmaceuticals giant Astrazeneca has reported double-digit sales growth on higher demand and said it remains committed to China despite the detention of a high-ranking staff member there. The FTSE 100 firm told markets this morning that total revenue rose 19 per cent to $39.2bn (£30.6bn) in the first nine months of the year. The London-listed [...]
Support for innovation is needed in Budget warns pharmaceutical industry October 15, 2024 The Association of the British Pharmaceutical Industry (ABPI) has called on Rachel Reeves to prioritise research and development (R&D) investment in the coming Labour Budget to unlock the potential of the UK life sciences sector. The APBI’s pre-Budget submission stressed the importance of maintaining and increasing public R&D funding to increase the UK’s attractiveness as [...]
GSK shares rise after £1.7bn Zantac settlement October 10, 2024 GSK shares have spiked today after the pharmaceutical giant agreed to pay as much as $2.2bn (£1.68bn) to settle lawsuits alleging one of its heartburn drugs had caused cancer. The discontinued version of the drug, Zantac, had triggered 80,000 lawsuits from 10 different law firms in the US and has hung over the FTSE 100 [...]
Meet the founder searching for the ‘holy grail’ of cancer treatment October 8, 2024 Jennifer Sieg speaks with Hilmar Warenius about how his discovery of a new type of cancer treatment could be well on its way to revolutionising the pharmaceutical industry
Astrazeneca boosts cardiovascular pipeline with licensing deal October 7, 2024 Astrazeneca has struck a licensing agreement worth up to $2bn (£1.5bn) with China’s CPSC Pharmaceutical Group to develop a new cardiovascular drug, the company announced on Monday. The Anglo-Swedish pharmaceutical giant will pay $100m (£76.5) upfront, with additional milestone payments of up to $1.9bn (£1.4bn), to licence a preclinical small molecule aimed at treating dyslipidemia. [...]
Vet service Animalcare reports positive results after balance sheet “transformation” September 24, 2024 International veterinary pharmaceutical and services business Animalcare has reported a “transformation” in its balance sheet after two sales worth £27.7m, as well as a boost in revenue. The AIM-listed, York-based company told markets this morning that its revenue rose by five per cent to £36.9m, from £35.2m in the first half of 2023. Underlying earnings [...]
AMS Group reports ‘strong’ first half amid rumoured takeover interest September 18, 2024 In the six months to June, revenue rose by eight per cent to £68.0m, with strong growth in the firm's surgical business unit offsetting "challenges" in its Woundcare unit.
Astrazeneca drags down the FTSE 100 following mixed cancer trial results September 10, 2024 Shares in Astrazenca and Daiichi Sankyo nose dived today after the pair revealed mixed results in their lung cancer drug's late-stage trial.